Merck KGaA, Darmstadt, Germany webcast presentation now available for on-demand viewing: dbVIC - Deutsche Bank ADR Virtual Investor Conference
PR Newswire
DARMSTADT, Germany, March 26, 2018
Company invites individual and institutional investors, as well as advisors, to log-on to view the presentation
DARMSTADT, Germany, March 26, 2018 /PRNewswire/ -- Merck KGaA, Darmstadt, Germany ((MRKMKKGY a leading science and technology company, today announced that their March 22, 2018 presentation is now available for on-demand viewing in the dbVIC Deutsche Bank American Depositary Receipt (ADR) Virtual Investor Conference.
LINK: https://tinyurl.com/dbvic03postpr
Merck KGaA, Darmstadt, Germany presentation will be available 24/7 for 90 days. Investors may download shareholder materials from the virtual trade booth in the Exhibits section of the event.
Recent Company Highlights
- Merck Achieves Targets for 2017 – Dividend to Increase
- Merck Announced Positive Phase IIB Results for Evobrutinib in Relapsing Multiple Sclerosis
- Mavenclad (Cladribine Tablets) Receives First Approval in Latin America, following approval in the EU, Canada, Australia and Israel
- Merck Receives Patents for CRISPR Technology in U.S., Brazil, China, India, Japan, South Korea and Israel
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2017, Merck KGaA, Darmstadt, Germany, generated sales of € 15.3 billion in 66 countries.
View original content:http://www.prnewswire.com/news-releases/merck-kgaa-darmstadt-germany-webcast-presentation-now-available-for-on-demand-viewing-dbvic---deutsche-bank-adr-virtual-investor-conference-300619171.html
SOURCE Merck KGaA
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.